Bayer recalls one lot of cancer drug Vitrakvi in US over microbial contamination
Customers who have the recalled lot should immediately stop use of the drug and contact their physician or healthcare provider, the company said.;
Advertisement
United States: Bayer said on Friday it was voluntarily recalling one lot of its cancer drug Vitrakvi in the U.S. due to the presence of microbial contamination that was observed during routine stability testing.
The company has not received any adverse event reports related to the lot to date, it said.
The drug, Vitrakvi, is approved for use in patients who have advanced solid tumor cancers with a rare gene mutation.
Read also: Bayer gets USFDA nod to FoundationOne CDx as Companion Diagnostic for larotrectinib
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.